VRTX250110P290000
- 0.00
- 0.000.00%
Vertex Pharmaceuticals Newsroom
First Earnings Show Beats are Back, December Jobs Climbed but Market Falls Friday | Live Stock
Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $460
Vertex Pharmaceuticals Analyst Ratings
Vertex Pharmaceuticals Incorporated (VRTX) Slid Due to Setbacks In Clinical Trials
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
Wells Fargo Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Cuts Target Price to $460
Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Cuts Target Price to $456
Express News | Zai Lab Ltd - to Handle Commercialization Activities for Povetacicept
Express News | Zai Lab Ltd - Vertex to Receive Upfront Payment, Milestone Payments, and Royalties
Vertex Pharmaceuticals: Hold Rating Amid Mixed Results for Suzetrigine in LSR and Optimistic Prospects in Acute Pain
Express News | Vertex Pharmaceuticals : Morgan Stanley Cuts Target Price to $456.00 From $476.00
Express News | Vertex Pharmaceuticals Incorporated : Wells Fargo Cuts Target Price to $460 From $555
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 42% Undervalued
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
S&P 500 Positive for 'First Five Days,' Huang Sees Decades till Quantum | Wall Street Today
Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
Vertex Grapples With Bearish Chart As Death Cross Emerges
Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock